<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Immunology Syngeneic Models Demonstrate Additive Effects of Combination Strategies using Checkpoint Immunotherapy and Inducers of Immunogenic Cell Death (ICD)

Recent progress in the field of cancer immunotherapy (IT) has made it possible to translate several emerging immunostimulatory strategies to the clinic, resulting in promising clinical benefits. In addition, a number of treatment strategies such as radiotherapy (RT), oncolytic viruses, and chemotherapeutic agents such as oxaliplatin, doxorubicin, bortezomib, and mitoxantrone have been highlighted as potential inducers of immunogenic cell death (ICD) through a well defined mechanism resulting in the increased presentation of cell-associated antigens to CD4+ and CD8+ T lymphocytes by dendritic cells.